Physician profile
Asra Ali
NPI 1144260217
$18,016.40
in general payments reported to CMS, 2019-2025
41 companies · $3,365 in 2025
The $3,365 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,682 · 2020: $686 · 2021: $2,695 · 2022: $2,887 · 2023: $3,475 · 2024: $3,227 · 2025: $3,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,967 · Education: $99.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,966.94 |
| Education | $99.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,177.09 | 2019-2025 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $1,955.20 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $1,847.23 | 2019-2025 | |
| Janssen Biotech, INC. | $1,499.31 | 2019-2025 | Tremfya, Remicade, Stelara |
| Sun Pharmaceutical Industries INC. | $1,484.43 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Amgen INC. | $856.94 | 2019-2025 | Otezla, Otezla |
| Leo Pharma INC. | $829.65 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $762.97 | 2019-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $712.87 | 2023-2025 | Zoryve |
| Genzyme Corporation | $594.77 | 2019-2025 | |
| Galderma Laboratories, L.P. | $566.49 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $532.42 | 2021-2025 | Opzelura |
| Ucb, INC. | $332.58 | 2021-2025 | Bimzelx |
| Pfizer INC. | $298.47 | 2022-2025 | |
| Dermavant Sciences, INC. | $273.25 | 2023-2024 | Vtama |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asra Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.